Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine added to standard therapy in heart failure with reduced ejection fraction
IRCT20240617062161N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jul 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Standard heart failure therapy plus colchicine with Standard heart failure therapy plus placebo (2 arms). Primary endpoints: hs-CRP plasma level, Interleukin-6 plasma level and 8 more. Started Jul 2024; status: completed.
02
Drugs
colchicine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on IRCT20240617062161N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240617062161N1.